Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda

Halozyme (NASDAQ: HALO) said a German court granted a preliminary injunction on Dec 4, 2025 ordering Merck to stop distributing and offering Keytruda SC in Germany for activity that would infringe European Patent No. 2 797 622 (EP 622) covering Halozyme's MDASE technology.

The order halts Merck's German launch activities within the injunction's scope; the decision is appealable and separate nullity proceedings filed by Merck in Aug 2025 are pending. Halozyme said Keytruda IV remains available and reiterated ongoing U.S. litigation alleging U.S. subcutaneous Keytruda (marketed as QLEX) infringes multiple MDASE patents.

https://www.stocktitan.net/news/HALO/halozyme-wins-preliminary-injunction-against-merck-s-keytruda-sc-in-v2j8scz5ivyt.html